| Title: |
Effect of Time to Start of Biologic Therapy on Treatment Response in Childhood Arthritis:Results From the UCAN CAN-DU Cohort |
| Authors: |
de Jonge, Jelleke B.; de Roock, Sytze; Schonenberg-Meinema, Dieneke; van den Berg,J. Merlijn; Marshall,Deborah A.; Vastert, Sebastiaan J.; Yeung,Rae S.M.; Swart, Joost F.; Benseler,Susanne M.; Huber,Adam; Lang,Bianca; DeCoste,Chelsea; Stringer,Elizabeth; Ramsey,Suzanne; Rosenberg,Alan; Neufeld,Kate; Jariwala,Mehul; Kerr,Tristan; Mosoiu,Alexander; Rachlis,Alisa; Xu,Amy; Cheng,Arthur; Jebb,Brenleigh; Feldman,Brian; Pereira,Bruno; Levy,Deborah; Dissanayake,Dilan; Limenis,Elizaveta; Rozenblyum,Evelyn; Cheng,Harper; Lee,Jennifer Ji Young; Spiegel,Lynn; Schneider,Rayfel; Laxer,Ronald; Verstegen,Ruud; Tse,Shirley; Duong,Trang; Human,Andrea; Cabral,David; Tam,Herman; Guzman,Jaime; Morishita,Kim; van Royen-Kerkhof, Annet; Prakken, Berent; Van Nieuwenhove, Erika; Jansen, Marc; Wulffraat, Nico; Legger, Elizabeth; Schatorje, Ellen; Kip, Michelle; the UCAN CAN-DU and UCAN CURE consortia; MS Algemene Pediatrie Onderzoek 2; CTI; Immuno/reuma onderzoek 7 (Swart); Immuno/reuma onderzoek 1 (Vastert); Child Health; Infection & Immunity; Immuno/reuma patientenzorg; CTI Van Loosdregt; Immunologie/Reumatologie; Geneeskunde; Onderwijscentrum Onderwijs; Immuno/reuma ERN; Reumatologie |
| Publication Year: |
2026 |
| Subject Terms: |
Immunology and Allergy; Rheumatology; Immunology; Journal Article |
| Description: |
Objective: To estimate the effect of time from symptom onset to start of biologic treatment on achieving inactive arthritis within six months in a cohort of patients with juvenile idiopathic arthritis (JIA). Methods: The international UCAN CAN-DU study prospectively enrolled patients with JIA across Canada and the Netherlands. A nested cohort study was performed and biologic-naive patients with nonsystemic JIA were included at the start of biologic therapy. The primary outcome was inactive arthritis at six months. Demographics, disease-related parameters, and treatment response were compared using (non)parametric tests among early (time symptom onset to biologic start: 0–6 months), intermediate (7–12 months), and late (13–24 months) treatment groups. A logistic regression model analyzed the effect of time to biologic start on the response at six months, adjusting for active joint count and physician global assessment. A graphical representation of the model was created. Results: One hundred and thirty children with JIA were included (early: n = 35; intermediate: n = 46; late: n = 49), 66% were female, and the median age at symptom onset was 11.0 years. The proportion of patients that reach inactive arthritis in the early starters (83%) was significantly higher than in late starters (57%). For each month of delay to the start of biologic treatment, the adjusted odds of having active arthritis after six months of therapy was 1.09 (interquartile range: 1.02–1.17, P = 0.009). Conclusion: Early start of biologic therapies in patients with JIA was associated with a higher proportion of patients reaching inactive arthritis within six months, suggesting a window of opportunity to control disease activity. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| ISSN: |
2326-5191 |
| Relation: |
https://dspace.library.uu.nl/handle/1874/483554 |
| Availability: |
https://dspace.library.uu.nl/handle/1874/483554 |
| Rights: |
info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.675D7AFA |
| Database: |
BASE |